Table 2. Correlation between plasma markers and outcomes by tumour type.
|
Carcinoid tumour |
pNET |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PFS |
OS |
PFS |
OS |
|||||||||
| Biomarker | Median (range) | N | P-values | HR (95% CI) | P-values | HR (95% CI) | Median (range) | N | P-values | HR (95% CI) | P-values | HR (95% CI) |
| VEGF Baseline, pg ml−1 | 30.1 (9.2–138.9) | 37 | 0.479 | 0.715 (0.280–1.826) | 0.86 | 0.325 (0.085–1.257) | 43.4 (8.2–408.5) | 64 | 0.237 | 1.533 (0.751–3.130) | 0.215 | 2.004 (0.653–6.146) |
| sVEGFR-2 Baseline, pg ml−1 | 8722 (3251–12 776) | 39 | 0.191 | 1.87 (0.72–4.88) | 0.698 | 0.797 (0.251–2.524) | 9562 (3894–15 689) | 65 | 0.206 | 0.639 (0.317–1.290) | 0.010 | 0.2152 (0.059–0.780) |
| sVEGFR-3 Baseline, pg ml−1 | 96800 (43 500–2 569 000) | 39 | 0.006 | 3.91 (1.38–11.10) | 0.047 | 3.227 (0.957–10.88) | 100 800 (30 700–168 400) | 65 | 0.091 | 0.549 (0.271–1.113) | 0.893 | 0.929 (0.319–2.706) |
| IL-8 Baseline, pg ml−1 | 15.0 (3.3–763.1) | 39 | 0.045 | 2.58 (0.985–6.780) | 0.014 | 5.507 (1.198–25.32) | 17.6 (6.1–130.3) | 65 | 0.135 | 1.700 (0.839–3.446) | 0.137 | 2.351 (0.737–7.503) |
Abbreviations: CI=confidence interval; HR=hazard ratio; IL-8=interleukin 8; OS=overall survival; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumour; sVEGFR-2= soluble VEGF receptor 2; sVEGFR-3=soluble VEGF receptor 3; VEGF=vascular endothelial growth factor.
P-values <0.05 are underlined and shown in bold.